BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
  • Home
  • About Us
    • Andrew Atkinson
    • Bruce Dyer
    • Clare Lowes
    • David Gazzard
    • Mark Tawn
    • Richard Lowes
  • Pain Conditions
    • CRPS Compensation
    • Fibromyalgia Solicitors
    • Myofascial Pain Syndrome Compensation Claim
    • Somatic Symptom Disorder Compensation Claim
    • Neuropathic Pain Compensation Claim
    • Functional Neurological Disorder Compensation
    • Chronic Fatigue Syndrome (ME) Compensation Claim
    • Chronic Pain Syndrome Compensation Claim
  • Unhappy With Your Solicitor?
  • Case Studies
    • Testimonials
  • Blog
  • Contact Us

Home » AT-121: new drug may be excellent opioid substitute

Chronic Pain Oct 4th, 2018
AT-121

AT-121: new drug may be excellent opioid substitute

In terms of pure pain-relieving qualities alone, it is difficult to deny that the best drugs available are opioids such as morphine and oxycontin.

However, with the war on opioids raging on both sides of the Atlantic, the race has been on to find a viable, but non-addictive alternative.

Now, an international team of researchers has published a paper in the journal, Science Translational Medicine, in which they reveal that they have developed a new synthetic drug called AT-121. They believe this drug may be as effective as opioids in its pain-relieving qualities, but without the risk of addiction and other common side-effects.

To date, trials have been limited to rhesus monkeys in whom there has been no sign of addiction or side-effects.

Bi-functional

The new drug has what are described as bi-functional qualities which means that it specifically targets two different opioid receptors in the brain, prohibiting their function. This in turn inhibits the sensation of pain.

The next stage is a thorough assessment of the drug’s safety, including the potential for side effects outside of the ones examined in this study. Subject to that, human trials could commence.

The need for speed

Despite the drug’s relatively early stage of development, the research team do not wish to lose their momentum. Team member, Dr Nurulain Zaveri, said “We want to move as fast as possible, because our results are exciting.”

And of course, there would be a huge financial incentive in getting this drug to market. The first viable opioid substitute has the potential to generate billions of dollars in sales revenue.

This research has certainly demonstrated that AT-121 has potential, with experts outside of the study also expressing considerable optimism. William Schmidt, a pharmaceutical consultant from North Star Consulting in California, said “They’ve got something here that’s really important. I think the chances of a compound with these properties moving forward are high, and simultaneously pretty exciting.”

You may also be interested in the following articles:

Hypnosis to treat CRPS: new research

Does immunotherapy treatment for CRPS have a future?

CRPS and menstruation

Can symptoms of CRPS be remitted using low-dose Naltrexone?

Stem Cell Therapy is here, but is it the long-awaited cure for CRPS?

Richard Lowes
Make an Enquiry

Contact Us

Contact Form

Left Column

Right Column

Centre

 
Sending

Recent Articles

  • Meet your chronic pain solicitor: Andrew Atkinson
  • CRPS on the rise but 62% of the UK have never heard of it
  • New fibromyalgia diagnostic guidelines
  • Could spider venom hold the key to treating chronic pain?
  • Study suggests Botox can prolong the benefit of a nerve block for CRPS

Share this Article

Newsletter Sign-up

* indicates required

Legal Glossary

Find Out More

You may also like...

  • Sep 19th, 2018
    Can a ‘volume control’ in the brain be targeted to treat neuropathic pain?
    Read Article
  • Oct 16th, 2018
    Medicinal Cannabis UK: an update
    Read Article
View All Related Articles

Get in Touch Today

Contact Form

Left Column

Right Column

Centre

 
Sending

1 Edgar Buildings,
George Street,
Bath, BA1 2DU

01225 462871 01225 445060
Authorised & Regulated by Solicitors Regulation Authority (No. 636644).
©2022 BLB Solicitors  |  Privacy & Terms